Aim: Recent studies have shown that the two-pore-domain potassium channel TREK-1 is involved in the proliferation of neural stem cells, astrocytes and human osteoblasts. In this study, we investigated how TREK-1 affected the proliferation of Chinese hamster ovary (CHO) cells in vitro. Methods: A CHO cell line stably expressing hTREK-1 (CHO/hTREK-1 cells) was generated. TREK-1 channel currents in the cells were recorded using whole-cell voltage-clamp recording. The cell cycle distribution was assessed using flow cytometry analysis. The expression of major signaling proteins involved was detected with Western blotting. Results: CHO/hTREK-1 cells had a high level of TREK-1 expression, reached up to 320%±16% compared to the control cells. Application of arachidonic acid (10 μmol/L), chloroform (1 mmol/L) or etomidate (10 μmol/L) substantially increased TREK-1 channel currents in CHO/hTREK-1 cells. Overexpression of TREK-1 caused CHO cells arresting at the G 1 phase, and significantly decreased the expression of cyclin D1. The TREK-1 inhibitor l-butylphthalide (1-100 μmol/L) dose-dependently attenuated TREK-1-induced G 1 phase cell arrest. Moreover, overexpression of TREK-1 significantly decreased the phosphorylation of Akt (S473), glycogen synthase kinase-3β (S9) and cAMP response element-binding protein (CREB, S133), enhanced the phosphorylation of p38 (T180/Y182), but did not alter the phosphorylation and expression of signal transducer and activator of transcription 3 (STAT3). Conclusion: TREK-1 overexpression suppresses CHO cell proliferation by inhibiting the activity of PKA and p38/MAPK signaling pathways and subsequently inducing G 1 phase cell arrest.
Introduction
Cell proliferation is a vital cellular function and is thus very strictly controlled by several independent mechanisms. It is widely believed that cell proliferation is closely related to potassium channel function, but the roles of these channels in this process are poorly understood. Many studies have demonstrated that numerous potassium channels control cell proliferation, among which Kv1.3 and KCa3.1 are crucial to the regulation of the proliferation of lymphocytes. Additionally, Kv11.1 (HERG), Kv10.1 (Eag1), and K2P 9.1 (TASK-3) have also been found to alter cell proliferation [1] . TREK-1 is a two-pore-domain potassium channel that contributes to background leak K + currents and is involved in the regulation of the resting membrane potentials of neurons and other tissues. TREK-1 is expressed throughout the central nervous system (CNS), particularly in the striatum and hippocampus [2] . The widespread expression of TREK-1 in small and medium diameter dorsal root ganglion (DRG) sensory neurons and the preoptic area and anterior hypothalamus makes this background K + channel an attractive candidate for a temperature sensor [3] . TREK-1 has been reported to be involved in multiple pathological processes. TREK-1 deficient (Kcnk2 -/-) mice exhibit a depression-resistant phenotype that mimics treatment with antidepressants [4] . Recently, the expression of TREK-1 has been found to be regulated by fluoxetine in the cortices of depressed animals [5, 6] . Moreover, other studies have demonstrated that TREK-1 activity increases glutamate clearance capability and inhibits inflammatory s100β secretion in cultured astrocytes following hypoxia [7, 8] . Additionally, our previous studies have demonstrated that both the mRNA and protein levels of TREK-1 were increased at 2 h after middle cerebral artery occlusion in the cortex and hippocampus [9] . Furthermore, in a long-term study using the above mentioned pathological model, the expression of TREK-1 significantly increased at d 3, 7, and 30 after the operation [10, 11] . Therefore, TREK-1 is involved in various cell functions, and it may become potential drug target for the treatment of CNS diseases.
Recently, some studies have found that TREK-1 may influence cell cycle progression. Up-regulation of TREK-1 at both the protein and mRNA levels leads to decreased neuronal stem cell (NSCs) proliferation that can be reversed with bupivacaine treatment. These findings indicate that TREK-1 may be involved in NSC proliferation after focal ischemia [5] . Several studies have demonstrated that TREK-1 inhibits both astrocyte proliferation under hypoxic conditions [10] and human osteoblasts proliferation [12] . We have previously found a negative relationship between TREK-1 expression and heart development in newborn rats and that the proliferation of normal and hypoxia-injured cardiac myocytes is induced by shRNA silencing of the TREK-1 gene [13] . However, some studies have demonstrated the opposite results. Voloshyna [14] and colleges demonstrated that the overexpression of TREK-1 increases the proliferation of prostate cancer cell lines. Therefore, the action and mechanisms of TREK-1 that influence cell proliferation remain unclear.
In the present study, we constructed a Chinese hamster ovary (CHO) cell line that stably expresses the human TREK-1 channel and investigated the effects of TREK-1 overexpression on proliferation. Specifically, we investigated the signaling pathways involved in this process and the effects of a TREK-1 inhibitor on cell proliferation.
Materials and methods

Plasmid construction
The following human KCNK2 variant a (NCBI Reference Sequence: NM_001017424, 422 amino acids)-specific primers containing Sac I or Kpn I sites were used: forward, 5'-AAGAGCTCCAAATGATGAACCCACGAGC-3'; and reverse, 5'-GGGGTACCGGCTCTTTGATGTTCTCAATC-3'. The PCR reaction mixes contained 10.0 μL 5× PCR buffer (Mg 2+ plus), 1.0 μL dNTPs (10 mmol/L), 1.0 μL of each primer (10 μmol/L), 4.0 μL template cDNA, and 0.5 μL Phusion ® High-Fidelity DNA polymerase (2 U/mL) (New England Biolabs, Hitchin, Herts, UK), and double distilled water was added to a total volume of 50 μL. The PCR reaction included pre-denaturation at 98 °C for 30 s and 35 amplification cycles each consisting of denaturation at 98 °C for 10 s, annealing at 65 °C for 30 s, and extension at 72 °C for 2 min. The PCR products were separated by electrophoresis on 1% ethidium bromide-stained agarose gel and visualized under UV light. The target fragment was purified with a gel extraction kit (TIAN-GEN, Beijing, China), and the PCR products and pEGFP-N1 vector were then digested with Sac I and Kpn I restriction enzymes. The digested pEGFP-N1 vector was ligated with the insert KCNK2 variant a cDNA with T4 DNA ligase to generate the eukaryotic expression vector pEGFP-N1-hTREK-1a. The recombinant vector was amplified in E coli DH5α and then extracted with a Qiagen Maxi plasmid kit (Qiagen, CA, USA). In the following experiments, the hTREK-1a-expressing CHO cell line was used.
Cell culture and transfection
The CHO cells were cultured in DMEM (Gibco, CA, USA) supplemented with 10% FBS (HyClone, UT, USA). The cells were grown at 37 °C in a humidified atmosphere containing 5% CO 2 and subcultured approximately every 3 d. When the CHO cells grew to 75%-80% confluence, the transfections were performed. Using MegaTran 1.0 transfection reagent (Origene, Beijing, China), the pEGFP-N1/hTREK-1a plasmid was transfected into the CHO cells. Fresh medium containing 0.8 mg/mL G418 was supplied to the transfected CHO cells 24 h after transfection, and a cell pool was obtained after 2 weeks of selection.
Electrophysiology
The membrane currents were recorded in the whole-cell voltage clamp configuration. Glass recording pipettes with resistances of 3-5 MΩ were used. The external solution contained the following (in mmol/L): NaCl, 150; KCl, 5.4; MgCl 2 , 2; CaCl 2 , 1.2; glucose, 15; and HEPES, 5 (titrated to pH 7.4 with NaOH). The patch pipette solution contained the following (in mmol/L): KCl, 140; MgCl 2 , 0.5; EGTA, 10; and HEPES, 10 (titrated to pH 7.2 with KOH). Currents were evoked in response to voltage ramps, and voltage steps were generated using an EPC-10 patch-clamp amplifier (HEKA Electronics, Lambrecht, Germany). The data were analyzed using Pulse 8.6 software (HEKA Electronics, Lambrecht, Germany). Before seal formation, the voltage offset between the patch electrode and the bath solution was adjusted to produce zero current. After seal formation (≥1 GΩ) and membrane rupture, the cells were allowed to stabilize for approximately 5 min. The holding potential during the experiments was set to -80 mV. All of the electrophysiological measurements were performed at room temperature (23-25 °C) .
Flow cytometric analysis of the cell cycle distribution
The protocol for the cell cycle analysis was that of the CyStain DNA 1 step kit (Partec, Munster, Germany). Briefly, the cells were seeded at 5×10 4 cells/well in 6-well plates. Twenty-four hours after seeding, fresh complete medium containing l-NBP (3-n-butylphthalide; 10, 30, and 100 μmol/L) or DMSO vehicle was added, and after 48 h of treatment, the CHO cells were trypsinized, centrifuged, and resuspended in 5 mL of PBS. The cells were spun down again, and the PBS was removed. One milliliter of CyStain DNA 1 step was added to the pellet, which was then vortexed and incubated for 5 min at room temperature. The sample was filtered through a 50-μm cell strainer and detected by flow cytometry with a Partec flow cytometer, and the data were analyzed with FCS Express software. 
Results
Expression and electrophysiological characteristics of the TREK-1 channels To study the biological functions of TREK-1, we generated a recombinant plasmid containing TREK-1 and transfected this plasmid into CHO cells (described above). After two weeks of culture in the presence of 0.8 mg/mL G418, a resistant cell pool was obtained. Cells transfected with pEGFP-N1 were used as controls (termed CHO/EGFP cells). We performed Western blot to detect and verify the expression of TREK-1 in the transfected CHO cells. The CHO/ hTREK-1 cells exhibited high levels of TREK-1 expression, whereas none of the controls yielded any visible bands. The value of the control group was taken as 100%, and the expression of TREK-1 in the CHO/hTREK-1 cells reached up to 320%±16% (P<0.01).
In the CHO/EGFP cells, a diffuse cytosolic EGFP labeling was present ( Figure 1A and 1B) , whereas the majority of the EGFP was localized to the membrane surface in the CHO/ hTREK-1 cells ( Figure 1C and 1D) . However, we and other groups have found that TREK-1 is substantially expressed in the nucleus [14] . Therefore, further studies are required to determine the significance of TREK-1 expression in the nucleus.
Polyunsaturated fatty acids and inhalational anesthetics have the ability to increase the activities of TREK-1 channels [15, 16] . Thus, we measured the activity of the TREK-1 channel expressed on the CHO/hTREK-1 cells using arachidonic acid (AA), chloroform (CHCl 3 ) and etomidate. As expected, 10 μmol/L AA, 1 mmol/L CHCl 3 , and 10 μmol/L etomidate substantially increased TREK-1 activity. The TREK-1 current was measured at the end of a voltage clamp pulse in the patch-clamp whole-cell recording mode. AA at 10 μmol/L increased the currents from 401±90 pA to 685±117 pA ( Figure  2A and 2B), CHCl 3 at 1 mmol/L increased the currents from 456±77 pA to 752±91 pA ( Figure 2C and 2D) , and etomidate at 10 μmol/L increased the currents from 405±154 pA to 649±202 pA ( Figure 2E and 2F) after depolarization from -80 mV to +60 mV. For convenience, we used enhanced green fluorescence protein (EGFP) as a tag, and our data revealed that the properties of the channel were unaltered by the presence of EGFP, results consistent with those from a previous study [12] . Hence, the CHO cells expressing human TREK-1 could be used to study the function of the TREK-1 channel.
TREK-1 overexpression inhibited the transition from the G 1 to the S phase in TREK-1 transfected cells, and this effect was reversed by l-NBP To evaluate the biological function of TREK-1 in proliferation, we used flow cytometry analyses to measure the cell cycle distributions of CHO/hTREK-1 and CHO/EGFP cells. The results indicated that human TREK-1 overexpression inhibited CHO cell proliferation. The percentage of the CHO/hTREK-1 cells entering the G 1 phase was 59.3%±2.6% ( Figure 3B ), which was higher than that in the CHO/EGFP cells (46.2%±0.3%, Figure 3A , P<0.01), and resulted in a corresponding decrease in the number of cells in the G 2 /M phase (P<0.01). Thus, these results suggest that TREK-1 might inhibit CHO cell growth by inhibiting the G 1 to S phase transition in the cell cycle.
Because the overexpression of TREK-1 inhibited CHO cell proliferation as demonstrated above, we next determined whether suppressing its activity would reverse the effect of TREK-1 on proliferation. The potent neuro-protectant 3-n-butylphthalide (NBP) was approved by the Food and Drug Administration of China (CFDA) at the end of 2002 as a new drug for the treatment of ischemic stroke, and NBP inhibits TREK-1 currents [17, 18] . Additionally, our previous study has demonstrated that the optical isomer l-NBP inhibits TREK-1 currents more potently than the dl-and d-NBP isomers, and l-NBP decreases the expression of TREK-1 [19, 20] . Therefore, we used the l-NBP as a TREK-1 inhibitor. As illustrated in Figure  3C , after 72 h of l-NBP treatment, the number of cells in the G 1 phase was significantly decreased compared with the CHO/ hTREK-1 cell control group. The cell numbers in the G 1 phase in the l-NBP groups the received 1, 3, 10, 30, and 100 µmol/L were 60.0%±0.3%, 59.6%±0.2%, 57.3%±0.2%, 53.3%±0.7%, and 42.5%±1.9%, respectively. These results suggested that TREK-1 inhibited the proliferation of CHO cells, however, the specific TREK-1 blocker l-NBP reversed the inhibitory effect of TREK-1 on cell proliferation. Consistently with the flow cytometry results, after l-NBP treatment (at 1, 50, and The TREK-1 currents were measured at +60 mV, and they increased from 401±90 pA to 685±117 pA after 10 μmol/L AA was applied (n=5). (C, D) The TREK-1 currents were measured at +60 mV, and they increased from 456±77 pA to 752±91 pA after 1 mmol/L CHCl 3 was applied (n=5). (E, F) The TREK-1 currents were measured at +60 mV, and they increased from 405±154 pA to 649±202 pA after 10 μmol/L etomidate was applied (n=4). Each bar presents the mean±SEM, and the data were analyzed with paired two-tailed Student's t-tests.
* P<0.05, ** P<0.01 compared with the control CHO/EGFP cells.
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Acta Pharmacologica Sinica 100 µmol/L), the cell viabilities were significantly increased compared with the control group according to MTT assays ( Figure 3D , P<0.01).
Cyclin D1 is down-regulated in TREK-1-overexpressing cells
To understand the molecular mechanisms of the effects of TREK-1 on cell proliferation, we detected the expression of cyclin D1 in the cells (Figure 4 ). Cyclin D1 is central to cell cycle arrest, the up-regulation or overexpression of cyclin D1 shortens the G 1 period, and cyclin D1 has been found in a variety of cancers [21] [22] [23] [24] [25] . The relative level in the control was taken 100%, and consistently with the cell cycle distributions, the levels of cyclin D1 decreased to 64.9%±6.8% in the TREK-1-overexpressing cells (P<0.01).
Reduced cyclin D1 expression due to decreased PKA and AKT signaling and CREB activity To further investigate the mechanism by which TREK-1 reduced the expression of cyclin D1 and inhibited cell proliferation, the phosphoinositide 3-kinase (PI3-K)/Akt signaling pathway, the cAMP-dependent protein kinase A (PKA)/cAMP response element binding protein (CREB) pathway, the Janus kinases (JAK)/signal transducer and activator of transcription (STAT) pathway and the mitogen-activated protein kinases (MAPK) pathway were examined (Figures 4 and 5) .
Western blot analysis of the phosphorylated Akt (p-AKT) levels indicated that the Akt activity was decreased in the CHO/hTERK-1 cells compared with the CHO/EGFP cells (Figure 4 ). In the CHO/hTREK-1 cells, the phosphorylation of Akt at Ser 473 was decreased to 71.7%±5.9% (Figure 4, P<0.05) , and no obvious changes in Akt phosphorylated at Thr 308 or the total Akt protein levels were observed, which demonstrated that TREK-1 decreased the activity of Akt by inhibiting the phosphorylation of Akt at Ser 473 rather than Thr 308 but had no effect on protein stability. In agreement with the decrease in the phosphorylation of Akt in the CHO/hTREK-1 cells, the phosphorylation of glycogen synthase kinase-3β (GSK-3β) at the Ser 9 site was down-regulated to 70.4%±11.0% ( Figure 4 , P<0.05), and no significant change in total GSK-3β was observed. We also examined the effect of TREK-1 on the PKA/CREB pathway. Ser133 as a key regulatory site that must be phosphorylated for CREB to stimulate the expressions of target genes. In the TREK-1 cells, the level of the PKA catalytic subunit was decreased to 66.7%±3.2% ( Figure 5, P<0.01) . Consistently with this result, the phosphorylation of CREB at Ser 133 was significantly decreased to 44.0%±5.7% (Figure 5 , P<0.01), whereas no obvious change in total CREB protein was observed.
In addition to the PKA/CREB and Akt signaling pathways, the p38 MAPK pathway also regulates cell cycle progression at different transition points by both transcriptiondependent and transcription-independent mechanisms [26] . Therefore, we detected the expression and phosphorylation of the p38 protein. Compared with the control group, the phosphorylation of the p38 protein was significantly increased to 141.2%±5.9% (P<0.05), whereas its expression exhibited no obvious change ( Figure 5 ).
Next, we assessed whether other signal pathways led to the down-regulation of cyclin D1. We also examined the effect of TREK-1 on the JAK/STAT pathway, and there were no obvious changes in the expression or phosphorylation of STAT3. These results indicated that STAT3 is not involved in the process of diminishing the expression of cyclin D1 ( Figure 5 ).
Discussion
In the present study, we constructed a CHO cell line that stably expressed the TREK-1 channel and studied the effects of TREK-1 on cell proliferation and the relevant signal pathways. Previous studies have indicated that enhanced expression of the mRNA and protein of TREK-1 by TREK-1 gene transfection suppresses the growth of NSCs and COS7 cells [5, 12] . Highly expressed TREK-1 might also inhibit the proliferation of astrocytes. Fluoxetine, which is a TREK-1 blocker, has also been found to inhibit the reduction in cell proliferation [27, 28] . In agreement with these reports, in the present study, we found that the overexpression of TREK-1 inhibited cell prolifera- According to our finding that G 1 is arrested by increased TREK-1 expression, we detected the expression of cyclin D1, which is a critical target of proliferative signals in G 1 phase. Cyclin D1 forms activating complexes with CDK4 and CDK6 that phosphorylate retinoblastoma tumor-suppressor protein (Rb) and prevent the binding of Rb with the E2F family, which activates the transcription of the cyclin E and thereby initiates the G 1 /S transition [29, 30] . Our results indicated that reduced cyclin D1 expression in the CHO/hTREK-1 cells led to inhibition of the proliferation these cells and specifically increased the percentage of cells in G 1 phase.
Many kinases and signaling pathways in the cell cycle are involved in controlling the level of cyclin D1. β-Catenin, CREB and STAT promote the transcription of cyclin D1, Akt increases the translation of cyclin D1, and GSK-3β, which is a downstream target of Akt, regulates the proteasomal degradation of cyclin D1 [31] . Additionally, the expression of cyclin D1 is also down-regulated by p38 [32] . We demonstrated that the overexpression of TREK-1 in the CHO/hTREK-1 cells resulted in the down-regulation of phosphorylated Akt, GSK-3β, and CREB as well as a reduction in the level of the PKA catalytic subunit. The overexpression TREK-1 also enhanced phosphorylated p38, whereas no obvious changes were observed in total or phosphorylated STAT3.
It has been suggested that TREK-1 interacts with A-kinaseanchoring proteins (AKAPs) and MAP2 [33] . PKA regulatory subunit type II (RII) has been found to bind with high affinity to AKAPs, whereas PKA regulatory subunit type I (RI) exhibits much lower affinity for AKAPs [34] . The ratio of between the regulatory subunits RI and RII is important [35] [36] [37] . We speculate that TREK-1 may recruit PKA RII subunits and down-regulate the level of the PKA catalytic subunit. Moreover, our data demonstrated TREK-1 increased the activity of GSK-3β and decreased the activity of CREB by reducing the phosphorylation of Akt at Ser473. Subsequently, the cell cycle was halted because of the inhibition of the transcription and translation of cyclin D1 and the promotion of the degradation of cyclin D1. Additionally, l-NBP, which is a potent and relatively selective inhibitor of TREK-1, reversed the effect of TREK-1 on cell proliferation; therefore, these findings support our previous research revealing that l-NBP promotes neuronal regeneration after ischemic stroke [38] . The regulation of the resting membrane potentials of neurons and the cells of other tissues is among the most vital functions of TREK-1. Previous data from our laboratory demonstrated that, compared with wild-type CHO cells, the resting membrane potential of TREK-1/CHO cells wasdecreased from -17.6 mV to -55.3 mV [19] . Moreover, many studies have demonstrated that the resting membrane potential modulates cell proliferation [39] [40] [41] , therefore, TREK-1 may control cell proliferation by hyperpolarizing the cell membrane potential.
Although many studies have suggested that inhibiting TREK-1 expression might promote cell proliferation, some authors have reported different results [14, 42] . Specifically, it has been reported that TREK-1 is highly expressed in prostate cancer cells but not in normal prostatic tissues [14] . The causal relationship between TREK-1 expression and cell proliferation in cancer cells is unclear. It is well known that the proliferation mechanisms of cancer cells are different and more complicated than those of normal cells. The proliferation of cancer cells might be promoted factors other than TREK-1. Notably, these authors were unable to directly demonstrate whether TREK-1 promoted tumor cells or whether channel expression was increased by compensation. Furthermore, 3 isoforms of TREK-1 (TREK-1a, TREK-1b, and TREK-1c) have been found, and these isoforms exhibit different N-terminal structures. It is unknown whether there are any functional differences among the isoforms. The TREK-1c variant (426 amino acids) differs in the 5' UTR and the beginning of the coding region compared with the TREK-1a variant. The TREK-1a isoform is slightly shorter and has a distinct N-terminus compared with the TREK-1c isoform. Voloshyna and colleagues used TREK-1c in their cancer cell and CHO cell study [14] . Additionally, in some cases, TREK-1 has been found to be up-regulated during organ/tissue damage [10, [43] [44] [45] . For example, TREK-1 expression is increased in acute cerebral ischemic stroke, and this increase might have a protective role for neuronal cells because enhanced TREK-1 currents may lower the resting membrane potential and reduce the excitability of the cells, consequently reducing energy consumption. Therefore, the increased expression of TREK-1 might be the result of compensation for the pathological condition and may reduce damage to the cells. In contrast, the inhibition of Figure 6 . Schematic diagram of the signaling pathways through which TREK-1 inhibits cell proliferation. TREK-1 inhibits the activity of PKA and then reduces the phosphorylations of CREB and Akt, which result in the inhibition of the expression of cyclin D1 and the induction of the degradation of cyclin D1, respectively. Therefore, CHO cell proliferation was inhibited due to the decrease in cyclin D1. TREK-1 increased the phosphorylation of p38, which also inhibited the expression of cyclin D1.
TREK-1 may promote neurogenesis after tissue damage such as the damage due to stroke [9, 38] . Therefore, TREK-1 is very important for tissue/cell protection and repair.
In conclusion, the present study demonstrated that the overexpression of TREK-1 in CHO cells inhibited the activity of PKA, increased the activity of p38, and consequently inhibited the expression of cyclin D1, which ultimately resulted in cell cycle arrest at G 1 /S. However, no correlation was observed between TREK-1 and activated STAT3. Although the regulatory mechanism of TREK-1 and PKA requires further research, the present study demonstrated important mechanisms by which TREK-1 inhibits the cell cycle. TREK-1 might be a drug target to promote neuronal proliferation and tissue recovery from damage.
